DelMar Pharmaceuticals, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.
In the following press release, the company presented new data on VAL-083 in the treatment of Glioblastoma multiforme including in vivo animal studies.
“We know that VAL-083 works through a different mechanism of action and does not show susceptibility to the same resistance mechanisms. The data we have been invited to present will show further evidence, in both in vivo animal studies, in vitro disease models and from our clinical studies, that indicate VAL-083 has the potential to provide a viable treatment option for patients suffering from GBM who fail or are unlikely to respond to currently available chemotherapy.” Read the full article.
DelMar Pharmaceuticals, Inc. is a clinical and commercial stage drug development company, which focuses on the research and development of drugs for the treatment of cancer. It offers VAL-083; drug discovery research; as well as patents and intellectual property. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in Vancouver, Canada. [Source: MarketWatch]
Company Website: http://www.delmarpharma.com